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The opioid epidemic is the most significant modern-day, public health crisis. Physicians and
lawmakers have developed methods and practices to curb opioid use. This article describes one
method, prescription drug monitoring programs (PDMP), through the lens of how to optimize use for
emergency departments (ED). EDs have rapidly become a central location to combat opioid abuse
and drug diversion. PDMPs can provide emergency physicians with comprehensive prescribing
information to improve clinical decisions around opioids. However, PDMPs vary tremendously in their
accessibility and usability in the ED, which limits their effectiveness at the point of care. Problems
are complicated by varying state-to-state requirements for data availability and accessibility.
Several potential solutions to improving the utility of PDMPs in EDs include integrating PDMPs with
electronic health records, implementing unsolicited reporting and prescription context, improving
PDMP accessibility, data analytics, and expanding the scope of PDMPs. These improvements
may help improve clinical decision-making for emergency physicians through better data, data
presentation, and accessibility. [West J Emerg Med. 2018;19(2)387–391.]

INTRODUCTION
Due to the growing opioid epidemic in the U.S., there
is widespread interest in using prescription drug monitoring
systems (PDMP) to curb prescription drug abuse. PDMPs
are statewide databases used by physicians, pharmacists,
and law enforcement to obtain data about controlled-drug
prescriptions, with the goal of detecting substance-use
disorders, drug-seeking behaviors, and reducing patient
risks of adverse drug events. While almost all U.S. states
have PDMPs, they vary in design and implementation.1 In
this paper, we review the history, evidence, and adoption
of best practice guidelines in state PDMPs with a focus on
how to best deploy PDMPs in emergency departments (ED).
Specifically, we analyze the current PDMP model and provide
recommendations for PDMP developers and EDs to help
meet the informational needs of ED providers with the goal of
better detection and prevention of prescription drug abuse.
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THE OPIOID CRISIS AND THE EMERGENCY
DEPARTMENT
The U.S. accounts for roughly 80% of opioid use
worldwide, and misuse – such as the recreational use of
opioids – is a significant problem.2 Every 19 minutes in the
U.S. someone dies from an unintentional drug overdose,
the majority from opioids.3 From 1997 to 2007 the average
milligram (mg)-per-year use of prescription per person of
opioids in the U.S. increased 402%, from 74 mg to 369 mg.
Meanwhile, an estimated seven million people above the age
of 12 use opioids and other prescription medications for nontherapeutic purposes annually.3,4 These non-medical uses of
opioids are linked to 700,000 ED visits yearly.3
Along with treating the consequences of opioid-related
illness and overdose, EDs are often a location used by some
patients as a source for opioid prescriptions.4 With limited time
and no prior patient relationship, emergency physicians (EP)
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must make quick decisions balancing the provision of sufficient
pain management against the potential for abuse and/or misuse.
It is sometimes difficult to detect who might be seeking to
misuse opioids. In one study, “classic” drug-seeking behaviors
were relatively ineffective in identifying high-risk patients.3
A Brief History of PDMPs and Their Effectiveness
PDMPs have been available for nearly 80 years. The first
state PDMP was established in California (1939), followed
by Hawaii (1943), Illinois (1961), Idaho (1967), New York
(1970), Pennsylvania (1972), Rhode Island (1978), Texas
(1981), and Michigan (1988).5 Early PDMPs were paper-based,
recordkeeping systems used primarily to provide reports to
law enforcement.5 By 1990 electronic key-punch databases
enabled easier data dissemination via PDMPs, and pharmacists
and clinicians began to use them.5 In 1996 the pharmaceutical
OxyContinTM was introduced; simultaneously, illicit prescription
drugs doubled from 1994-1998.5 In response, Congress signed
the Harold Rogers Prescription Monitoring Program grant into
law in 2002, providing the first guidelines and funding for states
to develop PDMPs.5 Since then, 49/50 states have now adopted
PDMPs. (Missouri is the only exception).6
Since the inception of PDMPs, studies have assessed
their impact on opioid prescribing and overdoses. Overall,
the literature has been mixed. Some studies have found no
relationship between PDMP implementation and outcomes;
however, most studies evaluated paper- or faxed-based
systems, with physicians receiving information days to weeks
after the initial request.4,7 In one such study, 21% of the
PDMPs evaluated were within their first years of operation or
had only recently come online.4 This is significant because in
states with new PDMPs, (Maine, New Mexico and Wyoming
[which became operational in 2004-2005]), many physicians
were not accessing or using data.4 This point is exemplified
through Virginia’s PDMP, which was established in 2007 and
was initially paper based.8 After moving to electronic and
real-time reporting, data requests exponentially increased from
74,342 in 2009 to 433,450 in 2010.8
Another factor limiting the effectiveness of PDMPs is that
each state has different policies and requirements for providers
to use them. Few states mandate prescriber use and in those
states that do not mandate use, compliance varies greatly.7 In
this context, it is logical to assume that if prescribers do not
access PDMP data, they cannot be effective.
VARIATION IN PDMP DESIGN AND
IMPLEMENTATION
A clear factor that leads to variation in observed
effectiveness is that PDMPs are not all designed in the same
way, particularly when it comes to their accessibility. Most
are representative of separate and distinct technological
and political environments at the time of their creation.5
According to the National Alliance for Model State Drug
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Laws study in late 2012, 38 state PDMPs are operated by a
state health agency and six are operated under the aegis of
law enforcement agencies.9 Additionally, 45 states monitor
schedule II-IV controlled substances, 34 states grant authority
to monitor schedule V substances, and 13 allow additional
monitoring of drugs not listed on Drug Enforcement
Administration schedules.9 Moreover, while several states
require physicians to access patient PDMP data before
prescribing controlled substances, the majority of states allow
for voluntary participation among physicians.9 Finally, 25
states provide unsolicited, automatic reports of suspicious
activity directly to law enforcement but only three (Delaware,
Louisiana, and West Virginia) automatically send reports
to multiple facilities including law enforcement, licensing
boards, pharmacies, and prescribers.9
However, states have looked to update and reformat their
PDMPs to better address the opioid crisis. For example, with
funding from the Core State Violence and Injury Prevention
Program, Oregon reformatted its PDMP to provide more
appropriate data to its EPs.10 Under this new funding, PDMPs
were designed to track schedule II-VI drugs prescribed within
Oregon as well as providing physicians with access to the
PDMP data of bordering states.10 Furthermore, pharmacies
within Oregon were required to report prescription data within
72 hours of opioid dispensing.10 Such interstate sharing and
tracking of all scheduled drugs has shown to provide safer
patient care. Since implementation, Oregon has reported a
38% decrease in the rate of prescription opioid overdose as
well as a 58% reduction in deaths related to methadone use.11
As sharing hubs such as those in Oregon, Michigan, Indiana
and Ohio are established, EPs may be better equipped to
successfully identify drug-seeking behavior.
PDMP design also leads to great variation in usability. For
example, some information displayed is not always relevant
or organized in a way that allows for EPs to answer specific
clinical questions that fit into ED workflow. In some systems,
frequent extraneous information is obtained simultaneously.2
Excessive data forces providers to search for relevant
information, squandering valuable time.
Furthermore, clinician training on how to use and
interpret PDMPs is often limited. Users are often left wading
through mountains of patient data seeking to piece together
a complete picture. One study surveyed physicians and
nurses from diverse specialties after PDMP use and found
that practitioners lacked guidance on data interpretation.12
In EDs time is a valuable resource and, unfortunately,
the complexity of some PDMPs limits their usability. For
example, in the current structure, PDMPs have experienced
growing compliance issues secondary to their difficulty of
use. In certain states, physicians are required to register with
their PDMP via a notarized medical license and government
identification.13 Password protocols exacerbate issues with
PDMP accessibility. Often physicians are required to meet
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excessive requirements for password security only to find that
within a short time their password has expired and the process
starts over. Passwords often cannot match previous entries
and involve multiple erroneous key elements to meet required
fields. Working in a fast-paced ED, having to frequently create
and update complicated passwords quickly transforms these
safeguards into a barrier to use.
Finally, not all PDMPs track all schedule drugs. Schedule
II drugs such as opioids have largely been the focus of
PDMPs, but other drugs categorized in alternative schedules
also have the potential for abuse. In 2011, for example,
ED visits for benzodiazepine abuse, a schedule IV drug,
was nearly equal to visits for opioids.14 ED records have
demonstrated a strong association with benzodiazepine abuse
and opioid abuse.15 Despite this potential for additional abuse,
only 34 PDMPs monitor schedule II-V drugs.16 To address
many of the usability limitations with PDMPs in EDs, we
suggest several ways to optimize their implementation.
Integration into ED Electronic Health Records
First, working to integrate the PDMPs with electronic health
records (EHR) is a key to effectively using PDMPs. Currently,
while clinicians are working in their hospital’s EHR system, most
have to open a web-browser and log in to a separate, secure page
with a separate username and password that is often a timeconsuming process, further deterring the widespread use of the
PDMP data. In the interest of time, physicians instead often resort
to using prior EHR data to make determinations about possible
drug seeking. Considering that EHR data is typically not shared
between facilities, physicians base decisions on significantly
smaller sample sizes. Indiana became the first state to merge an
EHR with the PDMP. The integration was found to be highly
effective with 58% of physicians prescribing fewer opioids
or smaller quantities after the implementation of the PDMP
data.17 Furthermore, integration of these systems could allow
for improvements through unsolicited reporting “alerts” on
the EHR for accessing physicians.18 These alerts could be used
much like a “sepsis alert,” indicating a questionable prescription
history of a patient immediately, allowing clinicians to further
investigate if needed.18
Unsolicited Reporting
Unsolicited reporting is a powerful tool through which
PDMPs can automatically send alerts for drug-seeking
behavior meeting a specific threshold to the appropriate
authority. Such quantitative thresholds have already been
implemented in several states with some success. In Virginia,
thresholds for individuals receiving 10 prescriptions from
10 providers (10x10) or (15x15) within a six-month period
were used.19 Subsequent periodic analysis of the data for
automatic, unsolicited reporting showed a steady decrease in
the number of individuals meeting thresholds, correlating to
a decrease in likely diversion and abuse.19 Such automated
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reporting does come with risk as such policies raise concerns
about patients being labeled an addict or postponing
necessary treatment.18 In addition, physicians treating cancer
patients or those requiring long-term opioid management
have expressed concern for their reputation and licensure.18
However, in the context of the newly-approved National
Quality Forum measures for limiting opioid prescribing,
PDMPs can take such measures into consideration and would
likely have an inverse effect by ensuring that guidelines are
followed and patients are treated safely.20
Providing Context for Opioid Prescriptions Through Data
Analytics
Data analytics and data visualization may be ways to help
contextualize opioid prescriptions for the busy EP. For example,
by linking prescriptions to a particular diagnosis physicians may
greatly reduce the guesswork involved for prescription behavior.
At a glance, a patient with multiple prescriptions for both shortand long-acting, opioid pain medications may appear to be an
opioid abuser. However, by tethering an explanatory diagnosis
to such prescriptions, after investigation this patient could be
found to have an extensive chronic pain condition warranting
multiple prescriptions. Therefore, fewer mental resources may
be required to rule out opioid abuse, reducing the potential for
misinterpreting data and in turn provide quicker and betterinformed emergency care.
Expanding the Accessibility to PDMPs Within the ED
Another common complaint from attending physicians
is the restriction allowing use of PDMPs only by licensed
and practicing attending physicians, and excluding resident
physicians. By allowing resident physicians access to PDMP
information, the clinical care team could be more efficient
particularly in academic settings where residents make many
clinical decisions. In addition, allowing other providers who
work in the ED, such as nurses and technicians, access to
PDMP data may further amplify their effectiveness and use as
a screening instead of a confirmation tool.
Expanding the Scope of PDMPs
PDMPs have an extensive capability for tracking drugseeking behavior and contacting the appropriate authorities
such as prescribers, pharmacies, licensing boards or law
enforcement. However, given that abuse is not limited to
opioid misuse, but includes benzodiazepines and other
schedule drugs as well, it is logical to assume that by
extending PDMP records to include tracking of all scheduled
drugs, PDMPs can have a greater impact against multiple
forms of doctor shopping, drug abuse and diversion.
Models of Well-designed PDMPs
Despite the issues highlighted above, some PDMPs
studies still suggest a positive trend between their use and
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subsequent decreases in opioid and prescription-drug abuse.
While opioid prescription overdose and abuse steadily
increased from 2002-2010, by 2011 opioid prescriptions
declined and consequently opioid overdose-related deaths
fell and abuse plateaued.21 As more modern PDMP systems
came online in conjunction with this decline, they are
thought to have played a role in by reducing prescriptions
in circulation and providing local governments with
better resources to identify illicit activity. Furthermore, in
Kentucky, Tennessee, New York and Ohio, early adopters
of mandated PDMP use have shown preliminary results
significant for a reduction in opioid prescribing as well
as declines in multiple providers prescribing or in doctor
shopping.7 Meanwhile, a 2016 study found a reduction on
average of 1.12 fewer, opioid-related overdose deaths per
100,000 cases annually by implementing a PDMP program.7
Finally, another 2016 study showed that from 2003-2009,
states without PDMPs experienced a steady increase in
opioid exposures of 1.9% per quarter annually, while states
with PDMPs in place experienced increases of only 0.2%.2
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